Schering-Plough Corp. has extended its collaboration with MorphoSys AG for one year. The collaboration, announced in May 2006, has a maximum term of five years until 2011 and may be extended by SP after each year. Under the agreement, SP will continue to have access to MorphoSys’s antibody library HuCAL GOLD at its research site in Palo Alto, CA, the location of Schering-Plough Biopharma. The contract also provides SP with the option to develop and commercialize HuCAL-derived therapeutic a...